Quando è indicata una biopsia prostatica?
Quando esiste un sospetto di tumore alla prostata, la diagnosi di certezza può avvenire solo attraverso l'esecuzione di una biopsia prostatica. L'indicazione a eseguire una biopsia prostatica dipende da numerosi fattori. I fattori predittivi più importanti sono il valore di PSA nel sangue, la familiarità per neoplasia prostatica e l'esplorazione rettale. Tuttavia per valutare correttamente il rischio individuale di tumore prostatico è necessario integrare queste informazioni con altre caratteristiche cliniche, quali l’età, il volume della prostata, la presenza di neoplasia prostatica intraepiteliale ad alto grado (HGPIN) o di proliferazione microacinare atipica (ASAP) in precedenti biopsie prostatiche.
In cosa consiste la biopsia prostatica?
La biopsia prostatica può essere eseguita su guida ecografica o su guida Risonanza Magnetica (biopsia RM fusion). Introducendo una sonda ad ultrasuoni attraverso il retto, si ottengono immagini accurate della ghiandola prostatica che possono indirizzare la biopsia verso quelle aree dove è potenzialmente presente un tumore prostatico. Il numero e la localizzazione dei prelievi è un aspetto fondamentale che l'urologo deve ponderare per poter raggiungere la massima accuratezza possibile. Negli ultimi anni sono stati sviluppati numerosi modelli predittivi statistici che, in base alle caratteristiche del paziente, suggeriscono la tipologia di schema bioptico da adottarsi. Dopo l’applicazione di un'anestesia locale, si eseguono prelievi bioptici del parenchima prostatico.
In preparazione alla procedura, il paziente deve richiedere alla struttura nella quale intende eseguire la manovra il documento che contiene le procedure di preparazione alla biopsia prostatica. Generalmente, tale preparazione richiede l'esecuzione di esami ematochimici di controllo (emocromo con formula, PT e PTT), un'urinocoltura, l'esecuzione di un clistere evacuativo e l'assunzione di una profilassi antibiotica.
Nel caso il paziente avesse:
-allergie a farmaci o sostanze
-terapie antiaggreganti piastriniche - e.g. cardioaspirina o cardirene - o terapie anticoagulanti - e.g. T.A.O.- in corso
-pregressi o recenti episodi di prostatite acuta o assunzioni prolungate di antibiotici
-alterazioni degli esami di preparazione alla biopsia
occorre prendere contatto con il medico che eseguirà la biopsia
Al momento della biopsia prostatica, il paziente deve fornire all'urologo le seguenti informazioni, fondamentali per la corretta indicazione ed esecuzione della manovra:
-valori di PSA o altri marcatori tumorali eseguiti
-familiarità per neoplasia prostatica
-esami ematochimici di preparazione nella norma (vedi sopra)
-allergie a farmaci o sostanze
-terapie domiciliari croniche (in particolare terapie antiaggreganti piastriniche - e.g. cardioaspirina o cardirene - o terapie anticoagulanti - e.g. T.A.O.)
-interventi chirurgici pregressi
-pregresse o recenti episodi di prostatite acuta o assunzioni prolungate di antibiotici negli anni precedenti
Queste informazioni permetteranno all'urologo di eseguire la procedura con la massima accuratezza diagnostica e limitando per quanto possibile la possibilità di complicazioni. Infatti, nonostante la mini-invasività della procedura, la biopsia prostatica può comportare la comparsa di:
-dolore (solitamente limitato alla durata della manovra)
-disuria - cioè sintomatologia irritativa nel mingere (frequente, per circa due settimane dalla manovra)
-lieve ematuria (frequente, per circa due settimane dalla manovra)
-lieve rettorragia (frequente, per circa due settimane dalla manovra)
-ritenzione urinaria acuta con necessità di cateterizzazione (rara, <10% delle manovre)
-febbre con o senza ospedalizzazione (rara, <10% delle manovre)
-macroematuria, uretrorragia o rettorragia che richiedono ospedalizzazione e manovre addizionali (rara, <5% delle manovre)
-urosepsi, cioe' una grave infezione generalizzata (rara, <3% delle manovre)
Di seguito sono riportati alcuni degli articoli scientifici pubblicati dal dr. Capitanio nell'ambito del tumore della prostatica (Fonte: Pubmed-Scopus Febbraio 2023):
1: CAPITANIO U, Pfister D, Emberton M. Repeat Prostate Biopsy: Rationale,
Indications, and Strategies. Eur Urol Focus. 2015 Sep;1(2):127-136. doi:
10.1016/j.euf.2015.05.002. Epub 2015 Jun 6. PMID: 28723423.
2: Scattoni V, Russo A, Di Trapani E, CAPITANIO U, La Croce G, Montorsi F.
Repeated biopsy in the detection of prostate cancer: when and how many cores.
Arch Ital Urol Androl. 2014 Dec 30;86(4):311-3. doi: 10.4081/aiua.2014.4.311.
PMID: 25641460.
3: Stabile A, Muttin F, Zamboni S, Moschini M, Gandaglia G, Fossati N,
Dell'Oglio P, CAPITANIO U, Cucchiara V, Mazzone E, Bravi CA, Mirone V, Montorsi
F, Briganti A. Therapeutic approaches for lymph node involvement in prostate,
bladder and kidney cancer. Expert Rev Anticancer Ther. 2019 Sep;19(9):739-755.
doi: 10.1080/14737140.2019.1659135. Epub 2019 Aug 30. PMID: 31469021.
4: Scattoni V, Maccagnano C, CAPITANIO U, Gallina A, Briganti A, Montorsi F.
Random biopsy: when, how many and where to take the cores? World J Urol. 2014
Aug;32(4):859-69. doi: 10.1007/s00345-014-1335-0. Epub 2014 Jun 8. PMID:
24908067.
5: CAPITANIO U. Contemporary management of patients with T1a and T1b prostate
cancer. Curr Opin Urol. 2011 May;21(3):252-6. doi: 10.1097/MOU.0b013e328344e4ad.
PMID: 21358335.
6: CAPITANIO U, Cheng L, Lopez-Beltran A, Scarpelli M, Freschi M, Montorsi F,
Montironi R. The importance of interaction between urologists and pathologists
in incidental prostate cancer management. Eur Urol. 2011 Jul;60(1):75-7. doi:
10.1016/j.eururo.2011.03.012. Epub 2011 Mar 16. Erratum in: Eur Urol. 2012
Aug;62(2):e47. PMID: 21444149.
7: Villa L, Capogrosso P, CAPITANIO U, Martini A, Briganti A, Salonia A,
Montorsi F. Silodosin: An Update on Efficacy, Safety and Clinical Indications in
Urology. Adv Ther. 2019 Jan;36(1):1-18. doi: 10.1007/s12325-018-0854-2. Epub
2018 Dec 6. PMID: 30523608.
8: Karakiewicz PI, CAPITANIO U, Shariat S. Editorial comment on: Prostate growth
and prevalence of prostate diseases in early onset spinal cord injuries. Eur
Urol. 2009 Jul;56(1):149-50. doi: 10.1016/j.eururo.2008.01.090. Epub 2008 Feb 8.
PMID: 18280634.
9: Dell'oglio P, Valiquette AS, Leyh-Bannurah SR, Tian Z, Trudeau V, Larcher A,
Shariat SF, CAPITANIO U, Briganti A, Graefen M, Montorsi F, Karakiewicz PI.
Treatment trends and Medicare reimbursements for localized prostate cancer in
elderly patients. Can Urol Assoc J. 2018 Jul;12(7):E338-E344. doi:
10.5489/cuaj.4865. Epub 2018 Mar 19. PMID: 29603911; PMCID: PMC6118049.
10: Scattoni V, Lazzeri M, Lughezzani G, De Luca S, Passera R, Bollito E,
Randone D, Abdollah F, CAPITANIO U, Larcher A, Lista G, Gadda GM, Bini V,
Montorsi F, Guazzoni G. Head-to-head comparison of prostate health index and
urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol. 2013
Aug;190(2):496-501. doi: 10.1016/j.juro.2013.02.3184. Epub 2013 Mar 1. PMID:
23466239.
11: Salonia A, Abdollah F, CAPITANIO U, Suardi N, Gallina A, Castagna G,
Clementi MC, Briganti A, Rigatti P, Montorsi F. Circulating sex steroids and
prostate cancer: introducing the time-dependency theory. World J Urol. 2013
Apr;31(2):267-73. doi: 10.1007/s00345-012-1009-8. Epub 2013 Jan 3. PMID:
23283410.
12: CAPITANIO U, Perrotte P, Hutterer GC, Suardi N, Jeldres C, Shariat SF,
Duclos A, Arjane P, Montorsi F, Karakiewicz PI. Effect of body mass index on
prostate-specific antigen and percentage free prostate-specific antigen: results
from a prostate cancer screening cohort of 1490 men. Int J Urol. 2009
Jan;16(1):91-5. doi: 10.1111/j.1442-2042.2008.02192.x. Epub 2008 Nov 27. PMID:
19054167.
13: CAPITANIO U, Autorino R, Bandini M, Briganti A, Cheng L, Cooperberg MR, Dehò
F, Gallina A, Klotz L, Lane B, Montironi R, Salonia A, Stief C, Tombal B,
Montorsi F. Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and
Research Entity and Should Be Fully Discussed in the International Prostate
Cancer Guidelines. Eur Urol Oncol. 2021 Apr 1:S2588-9311(21)00049-3. doi:
10.1016/j.euo.2021.03.005. Epub ahead of print. PMID: 33814342.
14: Salonia A, Abdollah F, CAPITANIO U, Suardi N, Briganti A, Gallina A, Colombo
R, Ferrari M, Castagna G, Rigatti P, Montorsi F. Serum sex steroids depict a
nonlinear u-shaped association with high-risk prostate cancer at radical
prostatectomy. Clin Cancer Res. 2012 Jul 1;18(13):3648-57. doi:
10.1158/1078-0432.CCR-11-2799. Epub 2012 May 15. PMID: 22589393.
15: CAPITANIO U, Briganti A, Gallina A, Suardi N, Karakiewicz PI, Montorsi F,
Scattoni V. Predictive models before and after radical prostatectomy. Prostate.
2010 Sep 1;70(12):1371-8. doi: 10.1002/pros.21159. PMID: 20623635.
16: CAPITANIO U, Autorino R, Bandini M, Briganti A, Cheng L, Cooperberg MR, Dehò
F, Gallina A, Klotz L, Lane BR, Montironi R, Salonia A, Stief C, Tombal B,
Montorsi F. Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der
Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur
Urol Oncol. In press: Incidental Prostate Cancer: An Example of How Important
Guidelines Are, Especially When Evidence Is Limited. Eur Urol Oncol. 2022
Apr;5(2):261-262. doi: 10.1016/j.euo.2021.05.004. Epub 2021 Jun 1. PMID:
34083164.
17: Maccagnano C, Gallina A, Roscigno M, Raber M, CAPITANIO U, Saccà A,
Pellucchi F, Suardi N, Abdollah F, Montorsi F, Rigatti P, Scattoni V. Prostate
saturation biopsy following a first negative biopsy: state of the art. Urol Int.
2012;89(2):126-35. doi: 10.1159/000339521. Epub 2012 Jul 19. PMID: 22814003.
18: Boehm K, Dell'Oglio P, Tian Z, CAPITANIO U, Chun FKH, Tilki D, Haferkamp A,
Saad F, Montorsi F, Graefen M, Karakiewicz PI. Comorbidity and age cannot
explain variation in life expectancy associated with treatment of non-metastatic
prostate cancer. World J Urol. 2017 Jul;35(7):1031-1036. doi:
10.1007/s00345-016-1963-7. Epub 2016 Oct 28. PMID: 27796538.
19: Spahn M, Briganti A, CAPITANIO U, Kneitz B, Gontero P, Karnes JR, Schubert
M, Montorsi F, Scholz CJ, Bader P, van Poppel H, Joniau S; European Multicenter
Prostate Cancer Clinical and Translational Research Group. Outcome predictors of
radical prostatectomy followed by adjuvant androgen deprivation in patients with
clinical high risk prostate cancer and pT3 surgical margin positive disease. J
Urol. 2012 Jul;188(1):84-90. doi: 10.1016/j.juro.2012.02.2572. Epub 2012 May 12.
PMID: 22578727.
20: Jeldres C, Isbarn H, CAPITANIO U, Zini L, Bhojani N, Shariat SF, Cloutier V,
Lattouf JB, Duclos A, Jolivet-Tremblay M, Valiquette L, Saad F, Graefen M,
Montorsi F, Perrotte P, Karakiewicz PI. Development and external validation of a
highly accurate nomogram for the prediction of perioperative mortality after
transurethral resection of the prostate for benign prostatic hyperplasia. J
Urol. 2009 Aug;182(2):626-32. doi: 10.1016/j.juro.2009.04.008. Epub 2009 Jun 17.
PMID: 19535100.
21: CAPITANIO U, Scattoni V, Freschi M, Briganti A, Salonia A, Gallina A,
Colombo R, Karakiewicz PI, Rigatti P, Montorsi F. Radical prostatectomy for
incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual
disease and biochemical recurrence. Eur Urol. 2008 Jul;54(1):118-25. doi:
10.1016/j.eururo.2008.02.018. Epub 2008 Feb 26. PMID: 18314255.
22: Dell'Oglio P, Bishr M, Boehm K, Trudeau V, Larcher A, Tian Z, Sosa J,
Moschini M, Saad F, CAPITANIO U, Briganti A, Graefen M, Montorsi F, Karakiewicz
PI. Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with
First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer. Eur
Urol Focus. 2018 Dec;4(6):834-841. doi: 10.1016/j.euf.2017.01.017. Epub 2017 Feb
11. PMID: 28753853.
23: Castiglione F, Benigni F, Briganti A, Salonia A, Villa L, Nini A, Di Trapani
E, CAPITANIO U, Hedlund P, Montorsi F. Naftopidil for the treatment of benign
prostate hyperplasia: a systematic review. Curr Med Res Opin. 2014
Apr;30(4):719-32. doi: 10.1185/03007995.2013.861813. Epub 2013 Dec 18. PMID:
24188134.
24: Briganti A, CAPITANIO U, Chun FK, Karakiewicz PI, Salonia A, Bianchi M,
Cestari A, Guazzoni G, Rigatti P, Montorsi F. Prediction of sexual function
after radical prostatectomy. Cancer. 2009 Jul 1;115(13 Suppl):3150-9. doi:
10.1002/cncr.24349. PMID: 19544544.
25: Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, CAPITANIO U, Gallina A,
Suardi N, Bianchi M, Tutolo M, Salonia A, Di Muzio N, Rigatti P, Montorsi F,
Blute M. Combination of adjuvant hormonal and radiation therapy significantly
prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a
matched analysis. Eur Urol. 2011 May;59(5):832-40. doi:
10.1016/j.eururo.2011.02.024. Epub 2011 Feb 22. PMID: 21354694.
26: Briganti A, CAPITANIO U, Chun FK, Gallina A, Suardi N, Salonia A, Da Pozzo
LF, Colombo R, Di Girolamo V, Bertini R, Guazzoni G, Karakiewicz PI, Montorsi F,
Rigatti P. Impact of surgical volume on the rate of lymph node metastases in
patients undergoing radical prostatectomy and extended pelvic lymph node
dissection for clinically localized prostate cancer. Eur Urol. 2008
Oct;54(4):794-802. doi: 10.1016/j.eururo.2008.05.018. Epub 2008 May 21. PMID:
18514383.
27: Ferrari M, CAPITANIO U, Rizzo N, Freschi M, Montorsi F, Rigatti P. Onset of
hydronephrosis and lower urinary tract symptoms in a previously healthy young
man: Phyllodes tumour of the prostate as a potential diagnosis. Can Urol Assoc
J. 2014 Jul;8(7-8):E561-3. doi: 10.5489/cuaj.1984. PMID: 25210565; PMCID:
PMC4137027.
28: CAPITANIO U, Suardi N, Briganti A, Gallina A, Abdollah F, Lughezzani G,
Salonia A, Freschi M, Montorsi F. Influence of obesity on tumour volume in
patients with prostate cancer. BJU Int. 2012 Mar;109(5):678-84. doi:
10.1111/j.1464-410X.2011.10453.x. Epub 2011 Jul 20. PMID: 21777363.
29: CAPITANIO U, Salonia A, Briganti A, Montorsi F. Silodosin in the management
of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who
are the best candidates. Int J Clin Pract. 2013 Jun;67(6):544-51. doi:
10.1111/ijcp.12135. Epub 2013 Feb 15. PMID: 23409749.
30: Rosiello G, Pecoraro A, Deuker M, Stolzenbach LF, Martin T, Tian Z, Larcher
A, CAPITANIO U, Montorsi F, Shariat SF, Kapoor A, Saad F, Briganti A,
Karakiewicz PI. The impact of sex and age on distribution of metastases in
patients with renal cell carcinoma. Int J Clin Oncol. 2021 May;26(5):962-970.
doi: 10.1007/s10147-021-01874-3. Epub 2021 Jan 30. PMID: 33515351.
31: Sharma G, Shah M, Ahluwalia P, Dasgupta P, Challacombe BJ, Bhandari M,
Ahlawat R, Rawal S, Buffi NM, Sivaraman A, Porter JR, Rogers C, Mottrie A, Abaza
R, Rha KH, Moon D, Yuvaraja TB, Parekh DJ, CAPITANIO U, Maes KK, Porpiglia F,
Turkeri L, Gautam G. Off-clamp Versus On-clamp Robot-assisted Partial
Nephrectomy: A Propensity-matched Analysis. Eur Urol Oncol. 2023 May
14:S2588-9311(23)00081-0. doi: 10.1016/j.euo.2023.04.005. Epub ahead of print.
PMID: 37193626.
32: Pozzi E, Ventimiglia E, Fallara G, Capogrosso P, Belladelli F, Candela L,
Raffo M, Costa A, Cignoli D, Corsini C, Cazzaniga W, Boeri L, Matloob R,
CAPITANIO U, Montorsi F, Salonia A. Haemospermia in the Real- Life Setting: A
New High-Risk Stratification. Urology. 2023 Jan;171:146-151. doi:
10.1016/j.urology.2022.09.018. Epub 2022 Oct 12. PMID: 36241064.
33: Briganti A, Passoni N, Ferrari M, CAPITANIO U, Suardi N, Gallina A, Da Pozzo
LF, Picchio M, Di Girolamo V, Salonia A, Gianolli L, Messa C, Rigatti P,
Montorsi F. When to perform bone scan in patients with newly diagnosed prostate
cancer: external validation of the currently available guidelines and proposal
of a novel risk stratification tool. Eur Urol. 2010 Apr;57(4):551-8. doi:
10.1016/j.eururo.2009.12.023. Epub 2009 Dec 18. PMID: 20034730.
34: Campi R, Amparore D, CAPITANIO U, Checcucci E, Salonia A, Fiori C, Minervini
A, Briganti A, Carini M, Montorsi F, Serni S, Porpiglia F. Assessing the Burden
of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies
During the COVID-19 Pandemic: Insights from Three Italian High-volume Referral
Centres. Eur Urol. 2020 Jul;78(1):11-15. doi: 10.1016/j.eururo.2020.03.054. Epub
2020 Apr 11. PMID: 32307215; PMCID: PMC7151319.
35: CAPITANIO U, Suardi N. Prostate cancer in 2010: GSU: misclassification or
biological progression? Nat Rev Urol. 2011 Feb;8(2):65-6. doi:
10.1038/nrurol.2010.247. PMID: 21304540.
36: CAPITANIO U, Cheng L, Lopez-Beltran A, Scarpelli M, Freschi M, Montorsi F,
Montironi R. Corrigendum to "The Importance of Interaction Between Urologists
and Pathologists in Incidental Prostate Cancer Management" [Eur Eurol
2011;60;75-7]. Eur Urol. 2012 Aug;62(2):e47. doi: 10.1016/j.eururo.2012.05.001.
Epub 2012 May 8. PMID: 27989299.
37: Bhojani N, Perrotte P, Hutterer G, Suardi N, Jeldres C, Shariat SF,
CAPITANIO U, Arjane P, Widmer H, Benard F, Peloquin F, Montorsi F, Karakiewicz
P. Body mass index and its association with genitourinary disorders in men
undergoing prostate cancer screening. J Sex Med. 2008 Sep;5(9):2141-51. doi:
10.1111/j.1743-6109.2008.00811.x. Epub 2008 Mar 19. PMID: 18355173.
38: Leyh-Bannurah SR, Zaffuto E, Dell'Oglio P, Tian Z, Moschini M, CAPITANIO U,
Briganti A, Montorsi F, Fisch M, Chun F, Kachanov M, Budäus L, Graefen M, Huland
H, Karakiewicz PI. Prediction of Complications in Radical Prostatectomy Prostate
Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes. Urol Int.
2019;102(1):51-59. doi: 10.1159/000495071. Epub 2018 Nov 27. PMID: 30481764.
39: Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Tian Z, Larcher A,
CAPITANIO U, Tilki D, Terrone C, Chun FKH, Antonelli A, Saad F, Shariat SF,
Montorsi F, Briganti A, Karakiewicz PI. Other-cause mortality and access to care
in metastatic renal cell carcinoma according to race/ethnicity. Urol Oncol. 2022
Nov;40(11):493.e9-493.e16. doi: 10.1016/j.urolonc.2022.06.022. Epub 2022 Jul 27.
PMID: 35907705.
40: Jeldres C, Suardi N, Perrotte P, CAPITANIO U, Walz J, Hutterer GC, Saad F,
Valiquette L, Graefen M, Widmer H, Karakiewicz PI. Survival after radical
prostatectomy and radiotherapy for prostate cancer: a population-based study.
Can Urol Assoc J. 2009 Feb;3(1):13-21. PMID: 19293970; PMCID: PMC2645889.
41: Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Martin T, Tian Z, Larcher
A, CAPITANIO U, Montorsi F, Shariat SF, Kapoor A, Saad F, Briganti A,
Karakiewicz PI. Partial nephrectomy in frail patients: Benefits of robot-
assisted surgery. Surg Oncol. 2021 Sep;38:101588. doi:
10.1016/j.suronc.2021.101588. Epub 2021 Apr 22. PMID: 33945961.
42: Abdollah F, Suardi N, CAPITANIO U, Gallina A, Sun M, Villa L, Scattoni V,
Bianchi M, Tutolo M, Fossati N, Karakiewicz P, Rigatti P, Montorsi F, Briganti
A. Spatial distribution of positive cores improves the selection of patients
with low-risk prostate cancer as candidates for active surveillance. BJU Int.
2013 Aug;112(4):E234-42. doi: 10.1111/bju.12152. Epub 2013 Jun 7. PMID:
23746297.
43: Villa L, CAPITANIO U, Briganti A, Abdollah F, Suardi N, Salonia A, Gallina
A, Freschi M, Russo A, Castiglione F, Bianchi M, Rigatti P, Montorsi F, Scattoni
V. The number of cores taken in patients diagnosed with a single microfocus at
initial biopsy is a major predictor of insignificant prostate cancer. J Urol.
2013 Mar;189(3):854-9. doi: 10.1016/j.juro.2012.09.100. Epub 2012 Sep 25. PMID:
23022004.
44: Dell'Oglio P, Suardi N, Boorjian SA, Fossati N, Gandaglia G, Tian Z,
Moschini M, CAPITANIO U, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A.
Predicting survival of men with recurrent prostate cancer after radical
prostatectomy. Eur J Cancer. 2016 Feb;54:27-34. doi: 10.1016/j.ejca.2015.11.004.
Epub 2015 Dec 19. PMID: 26707594.
45: Lughezzani G, Gallina A, Larcher A, Briganti A, CAPITANIO U, Suardi N, Lista
G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F.
Radical prostatectomy represents an effective treatment in patients with
specimen-confined high pathological Gleason score prostate cancer. BJU Int. 2013
May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4. PMID:
22487441.
46: Nocera L, Collà Ruvolo C, Stolzenbach LF, Wenzel M, Tian Z, Larcher A,
CAPITANIO U, Mirone V, Tilki D, Chun FKH, Kapoor A, Shariat SF, Saad F, Montorsi
F, Briganti A, Karakiewicz PI. Tumor Stage and Substage Predict Cancer-specific
Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological
Subtype-specific Validation. Eur Urol Focus. 2022 Jan;8(1):182-190. doi:
10.1016/j.euf.2021.02.009. Epub 2021 Feb 27. PMID: 33653677.
47: Scattoni V, Raber M, CAPITANIO U, Abdollah F, Roscigno M, Angiolilli D,
Maccagnano C, Gallina A, Saccà A, Freschi M, Doglioni C, Rigatti P, Montorsi F.
The optimal rebiopsy prostatic scheme depends on patient clinical
characteristics: results of a recursive partitioning analysis based on a 24-core
systematic scheme. Eur Urol. 2011 Oct;60(4):834-41. doi:
10.1016/j.eururo.2011.07.036. Epub 2011 Jul 30. PMID: 21820797.
48: Gandaglia G, Suardi N, Gallina A, CAPITANIO U, Abdollah F, Salonia A, Nava
L, Colombo R, Guazzoni G, Rigatti P, Montorsi F, Briganti A. Preoperative
erectile function represents a significant predictor of postoperative urinary
continence recovery in patients treated with bilateral nerve sparing radical
prostatectomy. J Urol. 2012 Feb;187(2):569-74. doi: 10.1016/j.juro.2011.10.034.
Epub 2011 Dec 15. PMID: 22177170.
49: Dell'Oglio P, Abou-Haidar H, Leyh-Bannurah SR, Tian Z, Larcher A, Gandaglia
G, Fossati N, Shariat SF, CAPITANIO U, Briganti A, Montorsi F, Graefen M, Saad
F, Karakiewicz PI. Assessment of the Rate of Adherence to International
Guidelines for Androgen Deprivation Therapy with External-beam Radiation
Therapy: A Population-based Study. Eur Urol. 2016 Sep;70(3):429-35. doi:
10.1016/j.eururo.2016.02.057. Epub 2016 Mar 4. PMID: 26951945.
50: Larcher A, Sun M, Dell'Oglio P, Trudeau V, Boehm K, Schiffmann J, Tian Z,
Fossati N, CAPITANIO U, Briganti A, Montorsi F, Karakiewicz P. Mortality,
morbidity and healthcare expenditures after local tumour ablation or partial
nephrectomy for T1A kidney cancer. Eur J Surg Oncol. 2017 Apr;43(4):815-822.
doi: 10.1016/j.ejso.2016.08.023. Epub 2016 Sep 17. PMID: 27692535.
51: Suardi N, Gallina A, Lista G, Gandaglia G, Abdollah F, CAPITANIO U,
Dell'Oglio P, Nini A, Salonia A, Montorsi F, Briganti A. Impact of adjuvant
radiation therapy on urinary continence recovery after radical prostatectomy.
Eur Urol. 2014 Mar;65(3):546-51. doi: 10.1016/j.eururo.2013.01.027. Epub 2013
Feb 4. PMID: 23415377.
52: CAPITANIO U, Briganti A, Suardi N, Gallina A, Salonia A, Freschi M, Rigatti
P, Montorsi F. When should we expect no residual tumor (pT0) once we submit
incidental T1a-b prostate cancers to radical prostatectomy? Int J Urol. 2011
Feb;18(2):148-53. doi: 10.1111/j.1442-2042.2010.02689.x. Epub 2010 Dec 30. PMID:
21198944.
53: Capogrosso P, CAPITANIO U, Vertosick EA, Ventimiglia E, Chierigo F, Oreggia
D, Moretti D, Briganti A, Vickers AJ, Montorsi F, Salonia A. Temporal Trend in
Incidental Prostate Cancer Detection at Surgery for Benign Prostatic
Hyperplasia. Urology. 2018 Dec;122:152-157. doi: 10.1016/j.urology.2018.07.028.
Epub 2018 Aug 20. PMID: 30138683; PMCID: PMC6724539.
54: Sharma G, Shah M, Ahluwalia P, Dasgupta P, Challacombe BJ, Bhandari M,
Ahlawat R, Rawal S, Buffi NM, Sivaraman A, Porter JR, Rogers C, Mottrie A, Abaza
R, Rha KH, Moon D, Yuvaraja TB, Parekh DJ, CAPITANIO U, Maes KK, Porpiglia F,
Turkeri L, Gautam G. Perioperative outcomes following robot-assisted partial
nephrectomy in elderly patients. World J Urol. 2022 Nov;40(11):2789-2798. doi:
10.1007/s00345-022-04171-4. Epub 2022 Oct 6. PMID: 36203102.
55: Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Nimer N, Tian Z,
Larcher A, CAPITANIO U, Tilki D, Terrone C, Chun FKH, Antonelli A, Saad F,
Shariat SF, Montorsi F, Briganti A, Karakiewicz PI. Contemporary vs historical
survival rates in metastatic clear cell renal carcinoma according to
race/ethnicity. World J Urol. 2022 Dec;40(12):2971-2978. doi:
10.1007/s00345-022-04183-0. Epub 2022 Oct 12. PMID: 36222885.
56: Fossati N, Sjoberg DD, CAPITANIO U, Gandaglia G, Larcher A, Nini A, Mirone
V, Vickers AJ, Montorsi F, Briganti A. Extended pelvic lymph node dissection in
patients with prostate cancer previously treated with surgery for lower urinary
tract symptoms. BJU Int. 2015 Sep;116(3):366-72. doi: 10.1111/bju.12912. Epub
2015 Jan 21. PMID: 25168453.
57: Tutolo M, Briganti A, Suardi N, Gallina A, Abdollah F, CAPITANIO U, Bianchi
M, Passoni N, Nini A, Fossati N, Rigatti P, Montorsi F. Optimizing postoperative
sexual function after radical prostatectomy. Ther Adv Urol. 2012
Dec;4(6):347-65. doi: 10.1177/1756287212450063. PMID: 23205061; PMCID:
PMC3491757.
58: Sharma G, Shah M, Ahluwalia P, Dasgupta P, Challacombe BJ, Bhandari M,
Ahlawat R, Rawal S, Buffi NM, Sivaraman A, Porter JR, Rogers C, Mottrie A, Abaza
R, Rha KH, Moon D, Yuvaraja TB, Parekh DJ, CAPITANIO U, Maes KK, Porpiglia F,
Turkeri L, Gautam G. Development and Validation of a Nomogram Predicting
Intraoperative Adverse Events During Robot-assisted Partial Nephrectomy. Eur
Urol Focus. 2023 Mar;9(2):345-351. doi: 10.1016/j.euf.2022.09.004. Epub 2022 Sep
22. PMID: 36153228.
59: Suardi N, Moschini M, Gallina A, Gandaglia G, Abdollah F, CAPITANIO U,
Bianchi M, Tutolo M, Passoni N, Salonia A, Hedlund P, Rigatti P, Montorsi F,
Briganti A. Nerve-sparing approach during radical prostatectomy is strongly
associated with the rate of postoperative urinary continence recovery. BJU Int.
2013 May;111(5):717-22. doi: 10.1111/j.1464-410X.2012.11315.x. Epub 2012 Jun 21.
PMID: 22726993.
60: Porter CR, Suardi N, CAPITANIO U, Hutterer GC, Kodama K, Gibbons RP, Correa
R Jr, Perrotte P, Montorsi F, Karakiewicz PI. A nomogram predicting prostate
cancer-specific mortality after radical prostatectomy. Urol Int.
2010;84(2):132-40. doi: 10.1159/000277588. Epub 2010 Mar 4. PMID: 20215815.
61: Dell'Oglio P, Tian Z, Leyh-Bannurah SR, Trudeau V, Larcher A, Moschini M, Di
Trapani E, CAPITANIO U, Briganti A, Montorsi F, Saad F, Karakiewicz PI. Short-
Form Charlson Comorbidity Index for Assessment of Perioperative Mortality After
Radical Cystectomy. J Natl Compr Canc Netw. 2017 Mar;15(3):327-333. doi:
10.6004/jnccn.2017.0032. PMID: 28275033.
62: Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Tian Z, Larcher A,
CAPITANIO U, Montorsi F, Shariat SF, Kapoor A, Saad F, Briganti A, Karakiewicz
PI. Preoperative frailty predicts adverse short-term postoperative outcomes in
patients treated with radical nephroureterectomy. J Surg Oncol. 2020
Mar;121(4):688-696. doi: 10.1002/jso.25840. Epub 2020 Jan 12. PMID: 31930511.
63: Salonia A, Abdollah F, CAPITANIO U, Gallina A, Suardi N, Briganti A, Zanni
G, Ferrari M, Castiglione F, Clementi MC, Rigatti P, Montorsi F. Preoperative
sex steroids are significant predictors of early biochemical recurrence after
radical prostatectomy. World J Urol. 2013 Apr;31(2):275-80. doi:
10.1007/s00345-012-0856-7. Epub 2012 Mar 24. PMID: 22441310.
64: Bravi CA, Gandaglia G, Mazzone E, Fossati N, Gallina A, Stabile A, Scuderi
S, Barletta F, Nocera L, Rosiello G, Martini A, Pellegrino F, Cucchiara V, Dehò
F, CAPITANIO U, Scattoni V, Salonia A, Briganti A, Montorsi F. Impact of Early
Dorsal Venous Complex Ligation on Urinary Continence Recovery after Robot-
assisted Radical Prostatectomy: Results from a Phase 3 Randomized Controlled
Trial. Eur Urol Focus. 2023 Jan;9(1):83-88. doi: 10.1016/j.euf.2022.09.003. Epub
2022 Sep 23. PMID: 36154808.
65: CAPITANIO U, Pellucchi F, Gallina A, Briganti A, Suardi N, Salonia A,
Abdollah F, Di Trapani E, Jeldres C, Cestari A, Karakiewicz PI, Montorsi F. How
can we predict lymphorrhoea and clinically significant lymphocoeles after
radical prostatectomy and pelvic lymphadenectomy? Clinical implications. BJU
Int. 2011 Apr;107(7):1095-101. doi: 10.1111/j.1464-410X.2010.09580.x. Epub 2010
Sep 29. PMID: 20880192.
66: Porter CR, Suardi N, Kodama K, CAPITANIO U, Gibbons RP, Correa R, Jeldres C,
Perrotte P, Montorsi F, Karakiewicz PI. A nomogram predicting metastatic
progression after radical prostatectomy. Int J Urol. 2008 Oct;15(10):889-94.
doi: 10.1111/j.1442-2042.2008.02105.x. Epub 2008 Jul 24. PMID: 18662174.
67: Dell'Oglio P, Zaffuto E, Boehm K, Trudeau V, Larcher A, Tian Z, Moschini M,
Shariat SF, Graefen M, Saad F, CAPITANIO U, Briganti A, Montorsi F, Karakiewicz
PI. Long-term survival of patients aged 80 years or older treated with radical
prostatectomy for prostate cancer. Eur J Surg Oncol. 2017 Aug;43(8):1581-1588.
doi: 10.1016/j.ejso.2017.02.018. Epub 2017 Mar 10. PMID: 28330822.
68: Abdollah F, Gandaglia G, Suardi N, CAPITANIO U, Salonia A, Nini A, Moschini
M, Sun M, Karakiewicz PI, Shariat SF, Montorsi F, Briganti A. More extensive
pelvic lymph node dissection improves survival in patients with node-positive
prostate cancer. Eur Urol. 2015 Feb;67(2):212-9. doi:
10.1016/j.eururo.2014.05.011. Epub 2014 Jun 2. PMID: 24882672.
69: Chun FK, Suardi N, CAPITANIO U, Jeldres C, Ahyai S, Graefen M, Haese A,
Steuber T, Erbersdobler A, Montorsi F, Huland H, Karakiewicz PI. Assessment of
pathological prostate cancer characteristics in men with favorable biopsy
features on predominantly sextant biopsy. Eur Urol. 2009 Mar;55(3):617-28-6.
doi: 10.1016/j.eururo.2008.04.099. Epub 2008 May 15. PMID: 18499335.
70: Abdollah F, Briganti A, Suardi N, Castiglione F, Gallina A, CAPITANIO U,
Montorsi F. Metabolic syndrome and benign prostatic hyperplasia: evidence of a
potential relationship, hypothesized etiology, and prevention. Korean J Urol.
2011 Aug;52(8):507-16. doi: 10.4111/kju.2011.52.8.507. Epub 2011 Aug 22. PMID:
21927696; PMCID: PMC3162215.
71: Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Tian Z, Kokorovic A,
Larcher A, CAPITANIO U, Tilki D, Terrone C, Chun FKH, Antonelli A, Saad F,
Shariat SF, Montorsi F, Briganti A, Karakiewicz PI. Cancer-specific Mortality in
T1a Renal Cell Carcinoma Treated with Local Tumor Destruction Versus Partial
Nephrectomy. Eur Urol Focus. 2023 Jan;9(1):125-132. doi:
10.1016/j.euf.2022.07.005. Epub 2022 Jul 30. PMID: 35918270.
72: Bhojani N, Salomon L, CAPITANIO U, Suardi N, Shariat SF, Jeldres C, Zini L,
Pharand D, Péloquin F, Arjane P, Abbou CC, De La Taille A, Montorsi F,
Karakiewicz PI. External validation of the updated partin tables in a cohort of
French and Italian men. Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):347-52.
doi: 10.1016/j.ijrobp.2008.04.082. Epub 2008 Nov 10. PMID: 19004573.
73: Rosiello G, Knipper S, Palumbo C, Dzyuba-Negrean C, Pecoraro A, Mazzone E,
Mistretta FA, Tian Z, CAPITANIO U, Montorsi F, Shariat SF, Saad F, Briganti A,
Karakiewicz PI. Unmarried status is a barrier for access to treatment in
patients with metastatic renal cell carcinoma. Int Urol Nephrol. 2019
Dec;51(12):2181-2188. doi: 10.1007/s11255-019-02266-3. Epub 2019 Aug 29. PMID:
31468289.
74: Bandini M, Smith A, Zaffuto E, Pompe RS, Marchioni M, CAPITANIO U, Chun FK,
Kapoor AB, Shariat SF, Montorsi F, Briganti A, Karakiewicz PI. Effect of
pathological high-risk features on cancer-specific mortality in non-metastatic
clear cell renal cell carcinoma: a tool for optimizing patient selection for
adjuvant therapy. World J Urol. 2018 Jan;36(1):51-57. doi:
10.1007/s00345-017-2093-6. Epub 2017 Oct 11. PMID: 29022072.
75: Sharma G, Shah M, Ahluwalia P, Dasgupta P, Challacombe BJ, Bhandari M,
Ahlawat R, Rawal S, Buffi NM, Sivaraman A, Porter JR, Rogers C, Mottrie A, Abaza
R, Rha KH, Moon D, Yuvaraja TB, Parekh DJ, CAPITANIO U, Maes KK, Porpiglia F,
Turkeri L, Gautam G. Comparison of perioperative outcomes following
transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: a
propensity-matched analysis of VCQI database. World J Urol. 2022
Sep;40(9):2283-2291. doi: 10.1007/s00345-022-04101-4. Epub 2022 Jul 22. PMID:
35867142.
76: Salonia A, Gallina A, Abdollah F, Briganti A, CAPITANIO U, Suardi N, Ferrari
M, Raber M, Colombo R, Freschi M, Rigatti P, Montorsi F. Preoperative
circulating sex hormones are not predictors of positive surgical margins at open
radical prostatectomy. World J Urol. 2012 Aug;30(4):533-9. doi:
10.1007/s00345-011-0761-5. Epub 2011 Sep 21. PMID: 21935733.
77: Capogrosso P, Ventimiglia E, Ferrari M, Serino A, Boeri L, CAPITANIO U,
Briganti A, Damiano R, Montorsi F, Salonia A. Long-term sexual outcomes after
holmium laser enucleation of the prostate: which patients could benefit the
most? Int J Impot Res. 2016 Sep;28(5):189-93. doi: 10.1038/ijir.2016.29. Epub
2016 Jul 28. PMID: 27465782.
78: Scattoni V, Raber M, Abdollah F, Roscigno M, Dehò F, Angiolilli D,
Maccagnano C, Gallina A, CAPITANIO U, Freschi M, Doglioni C, Rigatti P, Montorsi
F. Biopsy schemes with the fewest cores for detecting 95% of the prostate
cancers detected by a 24-core biopsy. Eur Urol. 2010 Jan;57(1):1-8. doi:
10.1016/j.eururo.2009.08.011. Epub 2009 Aug 19. PMID: 19720449.
79: Isbarn H, Jeldres C, CAPITANIO U, Zini L, Shariat SF, Lughezzani G, Sun M,
Ahyai SA, Duclos A, Jolivet-Tremblay M, Lattouf JB, Valiquette L, Perrotte P,
Montorsi F, Graefen M, Karakiewicz PI. Thirty-day mortality after transurethral
resection of the prostate in patients treated with androgen deprivation therapy.
J Endourol. 2009 Aug;23(8):1347-52. doi: 10.1089/end.2008.0618. PMID: 19591615.
80: Larcher A, Trudeau V, Dell'Oglio P, Tian Z, Boehm K, Fossati N, CAPITANIO U,
Briganti A, Montorsi F, Karakiewicz P. Prediction of Competing Mortality for
Decision-making Between Surgery or Observation in Elderly Patients With T1
Kidney Cancer. Urology. 2017 Apr;102:130-137. doi:
10.1016/j.urology.2016.08.069. Epub 2016 Nov 21. PMID: 27884597.
81: Karakiewicz PI, Bhojani N, CAPITANIO U, Reuther AM, Suardi N, Jeldres C,
Pharand D, Péloquin F, Perrotte P, Shariat SF, Klein EA. External validation of
the updated Partin tables in a cohort of North American men. J Urol. 2008
Sep;180(3):898-902; discussion 902-3. doi: 10.1016/j.juro.2008.05.044. Epub 2008
Jul 17. PMID: 18635222.
82: Dell'Oglio P, Bandini M, Leyh-Bannurah SR, Tian Z, Trudeau V, Larcher A,
Fossati N, Moschini M, Gandaglia G, CAPITANIO U, Briganti A, Graefen M, Montorsi
F, Saad F, Karakiewicz PI. External beam radiotherapy with or without androgen
deprivation therapy in elderly patients with high metastatic risk prostate
cancer. Urol Oncol. 2018 May;36(5):239.e9-239.e15. doi:
10.1016/j.urolonc.2018.01.004. Epub 2018 Feb 14. PMID: 29426698.
83: Abdollah F, Sun M, Briganti A, Thuret R, Schmitges J, Gallina A, Suardi N,
CAPITANIO U, Salonia A, Shariat SF, Perrotte P, Rigatti P, Montorsi F,
Karakiewicz PI. Critical assessment of the European Association of Urology
guideline indications for pelvic lymph node dissection at radical prostatectomy.
BJU Int. 2011 Dec;108(11):1769-75. doi: 10.1111/j.1464-410X.2011.10204.x. Epub
2011 Apr 20. PMID: 21507189.
84: Rosiello G, Pecoraro A, Luzzago S, Deuker M, Stolzenbach LF, Tian Z, Larcher
A, CAPITANIO U, Montorsi F, Shariat SF, Kapoor A, Saad F, Briganti A,
Karakiewicz PI. Prognostic factors in patients with small renal masses: a
comparison between <2 vs. 2.1-4 cm renal cell carcinomas. Cancer Causes Control.
2021 Feb;32(2):119-126. doi: 10.1007/s10552-020-01364-3. Epub 2020 Nov 9. PMID:
33169306.
85: Wagener N, Edelmann D, Benner A, Zigeuner R, Borgmann H, Wolff I, Krabbe LM,
Musquera M, Dell'Oglio P, CAPITANIO U, Klatte T, Cindolo L, May M, Brookman-May
SD; European Association of Urology (EAU) Young Academic Urologists (YAU) Kidney
Cancer Group. Outcome of papillary versus clear cell renal cell carcinoma varies
significantly in non-metastatic disease. PLoS One. 2017 Sep 21;12(9):e0184173.
doi: 10.1371/journal.pone.0184173. PMID: 28934212; PMCID: PMC5608215.
86: Briganti A, Larcher A, Abdollah F, CAPITANIO U, Gallina A, Suardi N, Bianchi
M, Sun M, Freschi M, Salonia A, Karakiewicz PI, Rigatti P, Montorsi F. Updated
nomogram predicting lymph node invasion in patients with prostate cancer
undergoing extended pelvic lymph node dissection: the essential importance of
percentage of positive cores. Eur Urol. 2012 Mar;61(3):480-7. doi:
10.1016/j.eururo.2011.10.044. Epub 2011 Nov 7. PMID: 22078338.
87: Abdollah F, Suardi N, Cozzarini C, Gallina A, CAPITANIO U, Bianchi M, Sun M,
Fossati N, Passoni NM, Fiorino C, Di Muzio N, Karakiewicz PI, Rigatti P,
Montorsi F, Briganti A. Selecting the optimal candidate for adjuvant
radiotherapy after radical prostatectomy for prostate cancer: a long-term
survival analysis. Eur Urol. 2013 Jun;63(6):998-1008. doi:
10.1016/j.eururo.2012.10.036. Epub 2012 Oct 26. PMID: 23122664.
88: Salonia A, Gallina A, Briganti A, Abdollah F, Suardi N, CAPITANIO U, Colombo
R, Freschi M, Rigatti P, Montorsi F. Preoperative hypogonadism is not an
independent predictor of high-risk disease in patients undergoing radical
prostatectomy. Cancer. 2011 Sep 1;117(17):3953-62. doi: 10.1002/cncr.25985. Epub
2011 Mar 1. PMID: 21365624.
89: Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Tian Z, Kokorovic A,
Larcher A, CAPITANIO U, Tilki D, Terrone C, Chun FKH, Antonelli A, Saad F,
Shariat SF, Montorsi F, Briganti A, Karakiewicz PI. Cancer-specific Mortality
After Cryoablation vs Heat-based Thermal Ablation in T1a Renal Cell Carcinoma. J
Urol. 2023 Jan;209(1):81-88. doi: 10.1097/JU.0000000000002984. Epub 2022 Nov 28.
PMID: 36440817.
90: Dell'Oglio P, Tian Z, Leyh-Bannurah SR, Larcher A, Mazzone E, Moschini M,
Trudeau V, Stabile A, Gallina A, Suardi N, CAPITANIO U, Mottrie A, Briganti A,
Montorsi F, Rochefort CM, Karakiewicz PI. Development of a New Comorbidity
Assessment Tool for Specific Prediction of Perioperative Mortality in
Contemporary Patients Treated with Radical Cystectomy. Ann Surg Oncol. 2019
Jun;26(6):1942-1949. doi: 10.1245/s10434-019-07313-y. Epub 2019 Mar 27. PMID:
30919224.
91: Abdollah F, Cozzarini C, Suardi N, Gallina A, CAPITANIO U, Bianchi M, Tutolo
M, Salonia A, La Macchia M, Di Muzio N, Rigatti P, Montorsi F, Briganti A.
Indications for pelvic nodal treatment in prostate cancer should change.
Validation of the Roach formula in a large extended nodal dissection series. Int
J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):624-9. doi:
10.1016/j.ijrobp.2011.06.2014. Epub 2011 Nov 16. PMID: 22099031.
92: Dell'Oglio P, Boehm K, Trudeau V, Tian Z, Larcher A, Leyh-Bannurah SR,
Moschini M, CAPITANIO U, Shariat SF, Briganti A, Montorsi F, Saad F, Karakiewicz
PI. Survival After Conservative Management Versus External Beam Radiation
Therapy in Elderly Patients With Localized Prostate Cancer. Int J Radiat Oncol
Biol Phys. 2016 Dec 1;96(5):1037-1045. doi: 10.1016/j.ijrobp.2016.05.004. Epub
2016 May 10. PMID: 27478167.
93: Abdollah F, Scattoni V, Raber M, Roscigno M, Briganti A, Suardi N, Gallina
A, CAPITANIO U, Freschi M, Salonia A, Cestari A, Guazzoni G, Rigatti P, Montorsi
F. The role of transrectal saturation biopsy in tumour localization:
pathological correlation after retropubic radical prostatectomy and implication
for focal ablative therapy. BJU Int. 2011 Aug;108(3):366-71. doi:
10.1111/j.1464-410X.2010.09876.x. Epub 2010 Nov 19. PMID: 21087451.
94: Gallina A, Maccagnano C, Suardi N, CAPITANIO U, Abdollah F, Raber M, Salonia
A, Scattoni V, Rigatti P, Montorsi F, Briganti A. Unilateral positive biopsies
in low risk prostate cancer patients diagnosed with extended transrectal
ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at
radical prostatectomy. BJU Int. 2012 Jul;110(2 Pt 2):E64-8. doi:
10.1111/j.1464-410X.2011.10762.x. Epub 2011 Nov 17. PMID: 22093108.
95: CAPITANIO U, Briganti A, Shariat SF, Karakiewicz PI. The importance of the
quantification of the extent of cancer in prostatic biopsies in prediction of
biochemical recurrence: a global perspective. Eur Urol. 2008 Oct;54(4):717-9.
doi: 10.1016/j.eururo.2008.07.034. Epub 2008 Jul 21. PMID: 18703272.
96: Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, CAPITANIO U, Bianchi M,
Tutolo M, Passoni NM, Salonia A, Colombo R, Freschi M, Rigatti P, Montorsi F.
Performance characteristics of computed tomography in detecting lymph node
metastases in contemporary patients with prostate cancer treated with extended
pelvic lymph node dissection. Eur Urol. 2012 Jun;61(6):1132-8. doi:
10.1016/j.eururo.2011.11.008. Epub 2011 Nov 12. PMID: 22099610.
97: Suardi N, Gallina A, CAPITANIO U, Salonia A, Lughezzani G, Freschi M,
Mottrie A, Rigatti P, Montorsi F, Briganti A. Age-adjusted validation of the
most stringent criteria for active surveillance in low-risk prostate cancer
patients. Cancer. 2012 Feb 15;118(4):973-80. doi: 10.1002/cncr.26234. Epub 2011
Jul 12. Erratum in: Cancer. 2012 May 1;118(9):2560. PMID: 21751185.
98: Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, Gallina A,
CAPITANIO U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C,
Guazzoni G, Montorsi F. Pelvic/retroperitoneal salvage lymph node dissection for
patients treated with radical prostatectomy with biochemical recurrence and
nodal recurrence detected by [11C]choline positron emission tomography/computed
tomography. Eur Urol. 2011 Nov;60(5):935-43. doi: 10.1016/j.eururo.2011.07.060.
Epub 2011 Aug 3. PMID: 21840116.
99: Larcher A, Trudeau V, Sun M, Boehm K, Meskawi M, Tian Z, Fossati N,
Dell'Oglio P, CAPITANIO U, Briganti A, Shariat SF, Montorsi F, Karakiewicz PI.
Population-based assessment of cancer-specific mortality after local tumour
ablation or observation for kidney cancer: a competing risks analysis. BJU Int.
2016 Oct;118(4):541-6. doi: 10.1111/bju.13326. Epub 2015 Oct 16. PMID: 26384713.
100: Briganti A, Suardi N, Capogrosso P, Passoni N, Freschi M, di Trapani E,
Gallina A, CAPITANIO U, Abdollah F, Tutolo M, Bianchi M, Salonia A, Da Pozzo LF,
Montorsi F, Rigatti P. Lymphatic spread of nodal metastases in high-risk
prostate cancer: The ascending pathway from the pelvis to the retroperitoneum.
Prostate. 2012 Feb 1;72(2):186-92. doi: 10.1002/pros.21420. Epub 2011 May 2.
PMID: 21538428.
101: Nocera L, Stolzenbach LF, Ruvolo CC, Wenzel M, Tian Z, Rosiello G, Bravi
CA, Candela L, Basile G, Larcher A, Shariat SF, Bertini R, CAPITANIO U, Salonia
A, Montorsi F, Briganti A, Karakiewicz PI. Predicting the risk of pT3a stage in
cT1 clear cell renal cell carcinoma. Eur J Surg Oncol. 2021 May;47(5):1187-1190.
doi: 10.1016/j.ejso.2020.10.040. Epub 2020 Nov 5. PMID: 33168336.
102: CAPITANIO U, Karakiewicz PI, Jeldres C, Briganti A, Gallina A, Suardi N,
Cestari A, Guazzoni G, Salonia A, Montorsi F. The probability of Gleason score
upgrading between biopsy and radical prostatectomy can be accurately predicted.
Int J Urol. 2009 May;16(5):526-9. doi: 10.1111/j.1442-2042.2009.02270.x. Epub
2009 Mar 26. PMID: 19389085.
103: Isbarn H, Jeldres C, Budäus L, Salomon G, Schlomm T, Steuber T, Chun FK,
Ahyai S, CAPITANIO U, Haese A, Heinzer H, Huland H, Graefen M, Karakiewicz P.
Effect of body mass index on histopathologic parameters: results of large
European contemporary consecutive open radical prostatectomy series. Urology.
2009 Mar;73(3):615-9. doi: 10.1016/j.urology.2008.09.038. Epub 2008 Nov 17.
PMID: 19010520.
104: Abdollah F, Sun M, Suardi N, Gallina A, CAPITANIO U, Bianchi M, Tutolo M,
Fossati N, Castiglione F, Freschi M, Karakiewicz P, Rigatti P, Montorsi F,
Briganti A. Presence of positive surgical margin in patients with organ-confined
prostate cancer equals to extracapsular extension negative surgical margin. A
plea for TNM staging system reclassification. Urol Oncol. 2013
Nov;31(8):1497-503. doi: 10.1016/j.urolonc.2012.04.013. Epub 2012 May 15. PMID:
22591746.
105: Salonia A, Gallina A, Briganti A, Suardi N, CAPITANIO U, Abdollah F,
Bertini R, Freschi M, Rigatti P, Montorsi F. Circulating estradiol, but not
testosterone, is a significant predictor of high-grade prostate cancer in
patients undergoing radical prostatectomy. Cancer. 2011 Nov 15;117(22):5029-38.
doi: 10.1002/cncr.26136. Epub 2011 Apr 14. PMID: 21495024.
106: Salonia A, Gallina A, Briganti A, Zanni G, Suardi N, CAPITANIO U, Colombo
R, Bertini R, Freschi M, Guazzoni G, Rigatti P, Montorsi F. Sex hormone-binding
globulin is a significant predictor of extracapsular extension in men undergoing
radical prostatectomy. BJU Int. 2011 Apr;107(8):1243-9. doi:
10.1111/j.1464-410X.2010.09582.x. Epub 2010 Sep 30. PMID: 20883480.
107: Marchioni M, Bandini M, Pompe RS, Martel T, Tian Z, Shariat SF, Kapoor A,
Cindolo L, Briganti A, Schips L, CAPITANIO U, Karakiewicz PI. The impact of
lymph node dissection and positive lymph nodes on cancer-specific mortality in
contemporary pT<sub>2-3</sub> non-metastatic renal cell carcinoma treated with
radical nephrectomy. BJU Int. 2018 Mar;121(3):383-392. doi: 10.1111/bju.14024.
Epub 2017 Oct 12. PMID: 28940649.
108: Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, Tian Z, Larcher A,
CAPITANIO U, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.
Histotype predicts the rate of lymph node invasion at nephrectomy in patients
with nonmetastatic renal cell carcinoma. Urol Oncol. 2020 May;38(5):537-544.
doi: 10.1016/j.urolonc.2020.01.013. Epub 2020 Feb 29. PMID: 32122729.
109: Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, St-Hilaire PA,
Tian Z, CAPITANIO U, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.
Comparison of survival outcomes in patients with metastatic papillary vs. clear-
cell renal cell carcinoma: a propensity-score analysis. World J Urol. 2021
Feb;39(2):461-472. doi: 10.1007/s00345-020-03187-y. Epub 2020 Apr 6. PMID:
32253579.
110: Suardi N, Briganti A, Gallina A, Salonia A, Karakiewicz PI, CAPITANIO U,
Freschi M, Cestari A, Guazzoni G, Rigatti P, Montorsi F. Testing the most
stringent criteria for selection of candidates for active surveillance in
patients with low-risk prostate cancer. BJU Int. 2010 Jun;105(11):1548-52. doi:
10.1111/j.1464-410X.2009.09057.x. Epub 2009 Nov 13. PMID: 19912205.
111: Briganti A, Di Trapani E, Abdollah F, Gallina A, Suardi N, CAPITANIO U,
Tutolo M, Passoni N, Salonia A, DiGirolamo V, Colombo R, Guazzoni G, Rigatti P,
Montorsi F. Choosing the best candidates for penile rehabilitation after
bilateral nerve-sparing radical prostatectomy. J Sex Med. 2012 Feb;9(2):608-17.
doi: 10.1111/j.1743-6109.2011.02580.x. Epub 2011 Dec 21. PMID: 22189164.
112: CAPITANIO U, Ventimiglia E, Montorsi F. The significance of a high
preoperative PSA level for the detection of incidental prostate cancer in LUTS
patients with large prostates. World J Urol. 2022 Apr;40(4):1063-1064. doi:
10.1007/s00345-021-03606-8. Epub 2021 Mar 2. PMID: 33651133.
113: Briganti A, Gallina A, Suardi N, CAPITANIO U, Tutolo M, Bianchi M, Passoni
N, Salonia A, Colombo R, Di Girolamo V, Guazzoni G, Rigatti P, Montorsi F.
Predicting erectile function recovery after bilateral nerve sparing radical
prostatectomy: a proposal of a novel preoperative risk stratification. J Sex
Med. 2010 Jul;7(7):2521-31. doi: 10.1111/j.1743-6109.2010.01845.x. Epub 2010 May
4. PMID: 20487236.
114: Gandaglia G, Suardi N, Gallina A, Abdollah F, CAPITANIO U, Salonia A,
Colombo R, Bianchi M, Chun FK, Hansen J, Rigatti P, Montorsi F, Briganti A.
Extended pelvic lymph node dissection does not affect erectile function recovery
in patients treated with bilateral nerve-sparing radical prostatectomy. J Sex
Med. 2012 Aug;9(8):2187-94. doi: 10.1111/j.1743-6109.2012.02812.x. Epub 2012 Jun
27. PMID: 22738395.
115: Zorn KC, CAPITANIO U, Jeldres C, Arjane P, Perrotte P, Shariat SF, Lee DI,
Shalhav AL, Zagaja GP, Shikanov SA, Gofrit ON, Thong AE, Albala DM, Sun L,
Karakiewicz PI. Multi-institutional external validation of seminal vesicle
invasion nomograms: head-to-head comparison of Gallina nomogram versus 2007
Partin tables. Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1461-7. doi:
10.1016/j.ijrobp.2008.06.1913. Epub 2008 Oct 19. PMID: 18938046.
116: Suardi N, CAPITANIO U, Chun FK, Graefen M, Perrotte P, Schlomm T, Haese A,
Huland H, Erbersdobler A, Montorsi F, Karakiewicz PI. Currently used criteria
for active surveillance in men with low-risk prostate cancer: an analysis of
pathologic features. Cancer. 2008 Oct 15;113(8):2068-72. doi:
10.1002/cncr.23827. PMID: 18792067.
117: Schiavina R, Gacci M, Briganti A, Imbimbo C, Simonato A, Borghesi M,
CAPITANIO U, Brunocilla E, Martorana G, Carini M, Montorsi F, Mirone V,
Carmignani G. Can side-specific biopsy findings predict the side of nodal
metastasis in clinically localized prostate cancer? Results from a multicenter
prospective survey. Eur J Surg Oncol. 2013 Sep;39(9):1019-24. doi:
10.1016/j.ejso.2013.06.017. Epub 2013 Jul 6. PMID: 23838373.
118: Bhojani N, CAPITANIO U, Suardi N, Jeldres C, Isbarn H, Shariat SF, Graefen
M, Arjane P, Duclos A, Lattouf JB, Saad F, Valiquette L, Montorsi F, Perrotte P,
Karakiewicz PI. The rate of secondary malignancies after radical prostatectomy
versus external beam radiation therapy for localized prostate cancer: a
population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys. 2010
Feb 1;76(2):342-8. doi: 10.1016/j.ijrobp.2009.02.011. PMID: 20117287.
119: Porter CR, CAPITANIO U, Perrotte P, Walz J, Isbarn H, Kodama K, Gibbons RP,
Correa R Jr, Karakiewicz PI. Adjuvant radiotherapy after radical prostatectomy
shows no ability to improve rates of overall and cancer-specific survival in a
matched case-control study. BJU Int. 2009 Mar;103(5):597-602. doi:
10.1111/j.1464-410X.2008.08133.x. Epub 2008 Nov 18. PMID: 19021603.
120: CAPITANIO U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti
A, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F. Biopsy
core number represents one of foremost predictors of clinically significant
gleason sum upgrading in patients with low-risk prostate cancer. Urology. 2009
May;73(5):1087-91. doi: 10.1016/j.urology.2008.10.048. Epub 2009 Feb 4. PMID:
19195695.
121: Gallina A, Ferrari M, Suardi N, CAPITANIO U, Abdollah F, Tutolo M, Bianchi
M, Saccà A, Salonia A, Rigatti P, Montorsi F, Briganti A. Erectile function
outcome after bilateral nerve sparing radical prostatectomy: which patients may
be left untreated? J Sex Med. 2012 Mar;9(3):903-8. doi:
10.1111/j.1743-6109.2011.02622.x. Epub 2012 Jan 12. PMID: 22240189.
122: Abdollah F, Sun M, Suardi N, Gallina A, CAPITANIO U, Bianchi M, Tutolo M,
Passoni N, Karakiewicz PI, Rigatti P, Montorsi F, Briganti A; National
Comprehensive Cancer Network. National Comprehensive Cancer Network practice
guidelines 2011: Need for more accurate recommendations for pelvic lymph node
dissection in prostate cancer. J Urol. 2012 Aug;188(2):423-8. doi:
10.1016/j.juro.2012.03.129. Epub 2012 Jun 13. PMID: 22698627.
123: González J, Gaynor JJ, Martínez-Salamanca JI, CAPITANIO U, Tilki D,
Carballido JA, Chantada V, Daneshmand S, Evans CP, Gasch C, Gontero P, Haferkamp
A, Huang WC, Espinós EL, Master VA, McKiernan JM, Montorsi F, Pahernik S, Palou
J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone
C, Vera-Donoso C, Zigeuner R, Hohenfellner M, Libertino JA, Ciancio G.
Association of an organ transplant-based approach with a dramatic reduction in
postoperative complications following radical nephrectomy and tumor thrombectomy
in renal cell carcinoma. Eur J Surg Oncol. 2019 Oct;45(10):1983-1992. doi:
10.1016/j.ejso.2019.05.009. Epub 2019 May 15. PMID: 31155470; PMCID: PMC8404534.
124: Briganti A, CAPITANIO U, Abdollah F, Gallina A, Suardi N, Bianchi M, Tutolo
M, Salonia A, Freschi M, Rigatti P, Montorsi F. Assessing the risk of lymph node
invasion in patients with intermediate risk prostate cancer treated with
extended pelvic lymph node dissection. A novel prediction tool. Prostate. 2012
Apr;72(5):499-506. doi: 10.1002/pros.21451. PMID: 22468270.
125: CAPITANIO U, Perrotte P, Zini L, Suardi N, Antebi E, Cloutier V, Jeldres C,
Shariat SF, Duclos A, Arjane P, Saad F, Montorsi F, Karakiewicz PI. Population-
based analysis of normal Total PSA and percentage of free/Total PSA values:
results from screening cohort. Urology. 2009 Jun;73(6):1323-7. doi:
10.1016/j.urology.2008.10.026. Epub 2009 Apr 18. PMID: 19376563.
126: Abdollah F, Briganti A, Suardi N, Gallina A, CAPITANIO U, Salonia A,
Cestari A, Guazzoni G, Rigatti P, Montorsi F. Does diabetes mellitus increase
the risk of high-grade prostate cancer in patients undergoing radical
prostatectomy? Prostate Cancer Prostatic Dis. 2011 Mar;14(1):74-8. doi:
10.1038/pcan.2010.41. Epub 2010 Oct 19. PMID: 20956995.
127: CAPITANIO U, Suardi N, Montorsi F, Briganti A. Editorial Comment to Risk
factors for pelvic lymphoceles post-radical prostatectomy. Int J Urol. 2011
Sep;18(9):644-5. doi: 10.1111/j.1442-2042.2011.02807.x. PMID: 21884261.
128: Montorsi F, Larcher A, CAPITANIO U. Re: Rohann J.M. Correa, Alexander V.
Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative
Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-
Analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2019.06.002.
Eur Urol Focus. 2021 Mar;7(2):406. doi: 10.1016/j.euf.2019.08.018. Epub 2019 Sep
26. PMID: 31564640.
129: Villa L, Salonia A, CAPITANIO U, Scattoni V, Abdollah F, Suardi N,
Dell'Oglio P, Freschi M, Montorsi F, Briganti A. The number of cores at first
biopsy may suggest the need for a confirmatory biopsy in patients eligible for
active surveillance-implication for clinical decision making in the real-life
setting. Urology. 2014 Sep;84(3):634-41. doi: 10.1016/j.urology.2014.02.070.
Epub 2014 Jul 22. PMID: 25059594.
130: CAPITANIO U, Ahyai S, Graefen M, Jeldres C, Shariat SF, Erbersdobler A,
Schlomm T, Haese A, Steuber T, Heinzer H, Perrotte P, Péloquin F, Pharand D,
Arjane P, Huland H, Karakiewicz PI. Assessment of biochemical recurrence rate in
patients with pathologically confirmed insignificant prostate cancer. Urology.
2008 Dec;72(6):1208-11; discussion 1212-3. doi: 10.1016/j.urology.2008.04.053.
Epub 2008 Aug 9. PMID: 18692880.
131: Gallina A, Suardi N, Montorsi F, CAPITANIO U, Jeldres C, Saad F, Graefen M,
Shariat SF, Widmer H, Arjane P, Péloquin F, Perrotte P, Karakiewicz PI.
Mortality at 120 days after prostatic biopsy: a population-based study of 22,175
men. Int J Cancer. 2008 Aug 1;123(3):647-52. doi: 10.1002/ijc.23559. PMID:
18470914.
132: Chun FK, Haese A, Ahyai SA, Walz J, Suardi N, CAPITANIO U, Graefen M,
Erbersdobler A, Huland H, Karakiewicz PI. Critical assessment of tools to
predict clinically insignificant prostate cancer at radical prostatectomy in
contemporary men. Cancer. 2008 Aug 15;113(4):701-9. doi: 10.1002/cncr.23610.
PMID: 18553365.
133: Salonia A, Briganti A, Gallina A, Karakiewicz P, Shariat S, Freschi M,
Zanni G, CAPITANIO U, Bosi E, Rigatti P, Montorsi F. Sex hormone-binding
globulin: a novel marker for nodal metastases prediction in prostate cancer
patients undergoing extended pelvic lymph node dissection. Urology. 2009
Apr;73(4):850-5. doi: 10.1016/j.urology.2008.09.026. Epub 2008 Nov 26. PMID:
19038425.
134: Briganti A, Tutolo M, Suardi N, Gallina A, Abdollah F, CAPITANIO U, Freschi
M, Bianchi M, Salonia A, Colombo R, Rigatti P, Montorsi F. There is no way to
identify patients who will harbor small volume, unilateral prostate cancer at
final pathology. implications for focal therapies. Prostate. 2012 Jun
1;72(8):925-30. doi: 10.1002/pros.21497. Epub 2011 Sep 30. PMID: 21965006.
135: Bhojani N, Ahyai S, Graefen M, CAPITANIO U, Suardi N, Shariat SF, Jeldres
C, Erbersdobler A, Schlomm T, Haese A, Steuber T, Heinzer H, Montorsi F, Huland
H, Karakiewicz PI. Partin Tables cannot accurately predict the pathological
stage at radical prostatectomy. Eur J Surg Oncol. 2009 Feb;35(2):123-8. doi:
10.1016/j.ejso.2008.07.013. Epub 2008 Sep 10. PMID: 18786800.
136: Jeldres C, Suardi N, CAPITANIO U, Montorsi F, Shariat SF, Perrotte P,
Peloquin F, Pharand D, Graefen M, Karakiewicz PI. High surgical volume is
associated with a lower rate of secondary therapy after radical prostatectomy
for localized prostate cancer. BJU Int. 2008 Aug;102(4):463-7. doi:
10.1111/j.1464-410X.2008.07705.x. Epub 2008 May 12. PMID: 18476966.
137: CAPITANIO U, Karakiewicz PI, Jeldres C, Briganti A, Salonia A, Cestari A,
Guazzoni G, Rigatti P, Montorsi F. Suspected clinical T3 prostate cancer is
associated with a high rate of negative extended biopsies: clinical
implications. Eur Urol. 2009 Jan;55(1):253-4. doi: 10.1016/j.eururo.2008.05.025.
Epub 2008 May 22. PMID: 18513849.